In Japan, clinical use is climbing faster, with about 4,500 people now on the drug. ARIA rates in Japan are half those in the U.S., which was also the case in the Phase 3 Clarity trial. Meanwhile, use ...
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback